Table 3.
Results of the Base-Case Analysis
| Population | All Patients | HR+Subgroup | ||
|---|---|---|---|---|
| Regimen | Chemotherapy | T-DXd | Chemotherapy | T-DXd |
| Health-state cost | ||||
| PFS state | 54,431.27 | 211,846.28 | 57,654.67 | 217,526.78 |
| PD state | 39,123.33 | 38,012.22 | 39,123.33 | 38,012.22 |
| Total cost | 93,554.6 | 249,858.5 | 96,778 | 255,539 |
| Difference | 156,303.9 | 158,761 | ||
| Health-state QALY | ||||
| PFS state | 0.519 | 0.948 | 0.548 | 0.974 |
| PD state | 0.517 | 0.539 | 0.563 | 0.607 |
| Total QALY | 1.036 | 1.487 | 1.111 | 1.581 |
| Difference | 0.451 | 0.47 | ||
| ICUR($/QALY) | 346,571.8 | 337,789.4 | ||
Abbreviations: LY, life-year; QALY, quality-adjusted life-year; ICUR, incremental cost-utility ratio; T-DXd, trastuzumab deruxtecan; HR+, hormone-receptor positive.